Abstract: Compounds of Formula 1 ##STR1## wherein m is 1-4; R.sub.1 --R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R.sub.5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R.sub.6 is hydrogen, lower alkyl, Cl, Br, I, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 OR NR.sub.11 --COR.sub.11 ; R.sub.20 is independently hydrogen or lower alkyl; Y is an aromatic group such as phenyl or naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.

Abstract: An improved method for isolating taxol and certain clinically important analogues of taxol from a crude extract of a naturally occuring Taxus species comprising treating the extract by reverse phase liquid chromatography on an adsorbent, causing the taxol and the taxol analogues to be absorbed on the adsorbent, and recovering taxol and the natural analogues of taxol from the adsorbent by elution with an elutant. The compounds thus isolated in pure form are taxol, taxol-7- xyloside, 10-deacetyltaxol, 10-deacetyltaxol-7-xyloside, cephalomannine, cephalomannine-7-xyloside, 10-deacetylcephalomannine-7-xyloside, baccatin III, 10-deacetylbaccatin III, baccatin VI, brevitaxane A, and taxiflorine.

Abstract: The new composition for use in washing and cleansing vulcanization molds in the manufacture of tires or other rubber items comprises: a) 10 to 90% of an amine mixture; b) 2 to 20% of a nonionic or anionic surface-active agent or a surface-active agent mixture; and c) 90 to 10% of a solvent.

Abstract: Cyclohexanedione derivatives of the general formula (I), ##STR1## wherein: R is a C.sub.1 -C.sub.4 alkyl group,each of R.sup.1 to R.sup.6 is independently hydrogen or a C.sub.1 -C.sub.4 alkyl group,X.sup.1 is a C.sub.1 -C.sub.4 alkyl group,X.sup.2 is hydrogen or a C.sub.1 -C.sub.4 alkyl group, andn is an integer of 0 to 2.or salta thereof exhibit high selectivity for corn, wheat and barley, can control gramineous weeds and broad-leaved weeds at a low dosage, and can be desirably used as an active ingredient of a herbicide.

Abstract: Thioalkane .alpha.,.beta.-diketones have interesting organoleptic properties and are therefore suitable as aroma substances.

Abstract: Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of .alpha..sub.1 adrenergic agonists are physiologically active compounds including N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties or monoalkyl carbon-substituted N.sup..delta. -substituted ornithine or N.sup..epsilon. -substituted lysine moieties, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is --NH.sub.2 when there is a double bond between the omega carbon and Q and Q' is .dbd.

Abstract: A therapeutic method is provided to elevate a depressed mammalian autologous mixed lymphocyte response and to alleviate the diseases associated therewith by the administration of an effective amount of certain selective delta opioid receptor antagonists to a mammal such as a human patient in need of such treatment.

Abstract: Organic carbonates containing at least one aromatic ester group can be obtained in a continuous manner from carbonates containing at least one aliphatic ester group and a phenolic compound in the presence of a transesterification catalyst known per se by carrying out the reaction in at least two stirred containers connected one behind the other in such a way that, in each case, the phenolic compound is metered in liquid form into the first stirred container and the carbonate containing at least one aliphatic ester group is metered in liquid form into one or more of the stirred containers. The carbonate containing at least one aromatic ester group is removed in liquid form from the last stirred container. Volatile reaction products, for example alcohol which has been cleaved out or a dialkyl carbonate are removed in gaseous form from one or more stirred containers.

Abstract: Tree growth is suppressed by placing an implant below the bark layer of the tree at each of a plurality of sites spaced around the circumference of the trunk of the tree, each implant containing a unit dose of active ingredient selected from flurprimidol, paclobutrazol, and uniconazole.

Abstract: Process for the diastereoselective reductive pinacol coupling of homochiral .alpha.-aminoaldehydesA process for the preparation of optically pure symmetrical compounds of the formula I ##STR1## is described in which R.sup.1, R.sup.2 and R.sup.3 are explained in the description, with simultaneous control of the four centers of chirality marked by *.

Abstract: Stoichiometric and catalytic chemical transformations may be carried out in solution using novel fluorous multiphase systems (FMS). The term "fluorous" is defined as a carbon-fluorine bond rich organic molecule. The FMS consists of a fluorous phase containing a fluorous solvent, typically a fluorocarbon or a fluorohydrocarbon and a reagent or a catalyst containing a sufficient number of fluorous moieties to render it preferentially soluble in the fluorous solvent without impairing the ability of the catalyst or reagent to be effective in the reaction and while maintaining the reaction in a liquid or fluid phase. The nonfluorous solvent may be any suitable organic or nonorganic solvent(s) with limited or no solubility in the fluorous solvent that is effective for dissolving the reactant(s) and most desirably, for separating the resulting product(s). Typically, such solvents have a Hildebrand solubility parameter of at least about 18.0 MPa1/2.

Abstract: Anti-diarrheal, anti-secretory, nitric oxide agonist, nitric oxide synthase activating or gastrointestinal anti-spasmodic compounds of the formula: ##STR1## wherein: R.sub.1 and R.sub.6 may be the same or different and are H, alkyl or aralkyl having from 1 to 12 carbon atoms;R.sub.2 -R.sub.5 may be the same or different and are H, R.sub.1 or R.sub.6 ;R.sub.7 is H, alkyl, aryl or aralkyl having from 1 to 12 carbon atoms;m is an integer from 3 to 6, inclusive; andn is an integer from 3 to 6, inclusive; or(IV) a salt thereof with a pharmaceutically acceptable acid; and a pharmaceutically acceptable carrier therefor. Methods of treatment utilizing the composition are also disclosed.

Abstract: Disclosed are a conductive thienyl derivative monomolecular film covalently bonded to a substrate surface and method of manufacturing the same, and a silicon compound comprising 3-thienyl groups (thiophene derivative) used for forming the conductive monomolecular film and a method of manufacturing the same. A monomolecular ultrathin film comprising 3-thienyl groups and silicon groups is formed in the invention. The silicon compound used for forming the film is provided by reacting .omega.-(3-thienyl)-1-alkene compound to a monosilane derivative compound, in which three out of four hydrogen atoms of monosilane are replaced with halogen or alkoxy groups, in the presence of a transition metal catalyst. A substrate is dipped and held in a nonaqueous solution of the above-noted compound, thus chemically bonding the monomolecular film to the substrate surface. Furthermore, a thienyl derivative ultrathin film is formed by the electrolytic or catalytic polymerization of the monomolecular film.

Abstract: Substituted benzofuran derivatives of the formula (I): ##STR1## wherein one of R.sub.1 and R.sub.2 is hydrogen or halogen and the other is, independently, an amino group or a C.sub.2 -C.sub.4 alkanoyl amino group; R.sub.3 is hydrogen; a linear or branched C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or C.sub.2 -C.sub.4 alkoxycarbonyl group; halogen; or phenyl unsubstituted or substituted by a C.sub.1 -C.sub.4 alkyl group; A is a group --(CH.sub.2).sub.n -Het wherein Het is an optionally substituted heteromonocyclic or heterobicyclic ring containing one or two nitrogen atoms, and n is zero or an integer of 1 to 3; and the symbol ..... represents a single or double bond; may be prepared by a process comprising reacting a compound of formula II: ##STR2## in which L is a leaving group and R.sub.4 is hydrogen or a carboxy protecting group, with a compound of formula III;R'.sub.3 --C.dbd.C--R'.sub.

Abstract: A process for the preparation of enantiomerically pure thienopyran derivatives of the formula ##STR1## is described. The thienopyran derivatives are relaxants of smooth muscle tone and as such are useful in vascular tissue for the treatment of hypertension disease, angina and other vascular disorders characterized by poor regional perfusion.

Abstract: A mosquito insecticidal composition and method for controlling the growth of mosquitos employing a mosquito insecticidally effective amount of a compound having one of the formulae: ##STR1## wherein: R.sub.1 and R.sub.6 may be the same or different and are alkyl having from 1 to 12 carbon atoms or hydrocarbyl aralkyl having up to 12 carbon atoms;R.sub.2 -R.sub.5 may be the same or different and are H, R.sub.1 or R.sub.6 ;R.sub.7 is H, alkyl having from 1 to 12 carbon atoms, hydrocarbyl aryl or hydrocarbyl aralkyl each having up to 12 carbon atoms;m is an integer from 3 to 6, inclusive;n is an integer from 3 to 6, inclusive; or(IV) a salt thereof with an acid and a carrier therefor.

Abstract: (S)-.alpha.-phenyl-2-pyridineethanamine, and its pharmaceutically acceptable derivatives, are useful in the treatment of neurodegenerative disorders, and exhibit linear pharmacokinetics.

Abstract: Novel cyclic amino acids which are useful in preparing biologically active peptides as well as a process for the preparation of D and L enantiomers of the cyclic amino acids are described where an N-protected derivative of the racemic cyclic amino acid is treated with (-)cinchonidine and the resulting salt resolved into the desired enantiomers, as well as derivatives thereof and valuable intermediates used in the process.

Abstract: Combinations of active substances of the formula (I) ##STR1## where R.sup.1 is halogen, lower alkoxy, alkyl or haloalkyl, NO.sub.2, CN, (S(O).sub.n R.sup.10 [sic],R.sup.2 and R.sup.3 are H, halogen, lower alkyl, alkoxy, haloalkoxy or haloalkyl, CN, NO.sub.2, S(O).sub.m R.sup.11, NR.sup.11 R.sup.13, NR.sup.14 --COR.sup.15, CO--R.sup.16,R.sup.4 and R.sup.6 -R.sup.9 are H or lower alkyl,R.sup.5 is H, lower alkyl or alkyl--O--CO--,R.sup.10 is lower alkyl, haloalkyl or alkoxy,R.sup.11 is lower alkyl or haloalkyl or phenyl, benzyl or NR.sup.17 R.sup.18,R.sup.12 and R.sup.13 are H or lower alkyl,R.sup.14 is H or lower alkyl,R.sup.15 is lower alkyl,R.sup.16 is H, lower alkyl, haloalkyl or alkoxy,R.sup.17 and R.sup.18 are H or lower alkyl,n and m in each case are 0 to 2, with herbicides from the group comprising fenoxaprop-ethyl, fenoxaprop-P-ethyl, quinchlorac, molinate, thiobencarb, butachlor, pretilachlor, mefenacet, esprocarb, dimepiperate, HW-52; cinmethylin, anilophos, benfuresate, triazofenamide,.

Abstract: The present invention provides a novel imidazole derivative having the chemical formula ##STR1## These compounds are useful for preventing or treating hypertension or congestive heart failure and have high activity, rapid action upon intravenous injection, good oral absorbtion, low toxicity, and long-lasting action. Also provided are pharmaceutical compositions which contain these compounds.